Navigation Links
Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
Date:12/6/2010

cal activity and survival.

Ron Bentsur, CEO of Keryx, commented, "The data presented at the ASH meeting further demonstrate perifosine's potential beyond the ongoing Phase 3 registration trials in metastatic colorectal cancer and multiple myeloma. It is encouraging to see perifosine's activity as a single agent and in combination with sorafenib in heavily pre-treated, advanced CLL and HL patients, respectively. Moreover, the perifosine-Revlimid® (+ dexamethasone) combination data in multiple myeloma also presented at ASH indicate that the combination is well tolerated demonstrating promising clinical activity."

Perifosine is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.  Both of these Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA, and with Fast Track designations obtained for both indications. Perifosine is also in Phase 1 and 2 clinical development for several other tumor types.

KRX-0401 (perifosine) is in-licensed by Keryx from Aeterna Zentaris Inc. in the United States, Canada and Mexico.

About Keryx Biopharmaceuticals, Inc.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Phase III Data Published in Lancet Show Novartis Drug Zometa® Improves Overall Survival in Newly Diagnosed Multiple Myeloma Patients
2. Neuraltus Pharmaceuticals Reports Clinical Results from Phase 1/2 NP002 Study in the Treatment of Dyskinesias Resulting from Levodopa Therapy for Parkinsons Disease
3. Spherix Announces Post-Hoc Analysis of Phase 3 Trial With D-Tagatose in Diabetes
4. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
5. Circassia Achieves Major Reduction in Allergic Reactions to House Dust Mite in Phase II Clinical Study of Novel T-cell Vaccine
6. Sangamo BioSciences Announces Presentation of Phase 2 Data in Amyotrophic Lateral Sclerosis (ALS) at Society for Neuroscience Meeting
7. VIDEO from Merck and Co., Inc available on thenewsmarket.com: In Phase III Study Mercks Investigational CETP Inhibitor Anacetrapib Met Safety and Efficacy Endpoints in Patients with CHD
8. Cardio3 BioSciences Announces Positive Outcome of the C-Cure(R) Phase II Clinical Trial in Heart Failure Patients
9. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
10. Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/20/2014)... SAN MARCOS, Texas , Aug. 20, 2014 ... purchase of five diverse sets of patent families ... and major innovation driver for Bayer AG of ... The patents acquired provide broad intellectual property ... achieved in economical high-volume quantum dot (QD) manufacturing. ...
(Date:8/20/2014)... 20, 2014 Phase I Trial ... US  KalVista Pharmaceuticals ("KalVista"), an ophthalmology company ... announces that it has begun a Phase I, First ... KVD001, for the treatment of DME. The study,s Principal ... Eye Institute, Joslin Diabetes Center; Harvard Medical School Department ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 2Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 3Quantum Materials Acquires Bayer Technology Services Quantum Dot Manufacturing and Quantum Dot Solar Cell Patents 4KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 2KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 3KalVista Pharmaceuticals Announces Start of Clinical Development for Novel Treatment for Diabetic Macular Edema 4
... Therapeutics,(Amex: CXM ) and its operating ... from a preclinical study, demonstrating a new ... for the potential,treatment of acute myocardial infarction ... Central (BMC) Cardiovascular Disorders (2008, 8:7, April,10, ...
... Regimen Designed to Avoid Risk of Toxicity ... Associated with Nucleoside Class of HIV Drugs, ... ) today announced that it has initiated a Phase ... in first-line therapy of adult treatment-naive HIV-infected patients,with R5-type ...
Cached Medicine Technology:Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 2Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 3Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 4Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 5Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 6Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 7Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 8Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 9Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 10Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 11Cardium's Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack 12Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 2Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 3Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 4Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 5Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients 6
(Date:8/20/2014)... 42 percent of women underwent breast reconstruction following ... with foregoing reconstruction included being black, having a ... Monica Morrow, M.D., of the Memorial Sloan Kettering ... The Women,s Health and Cancer Rights Act in ... a mastectomy. Still, most women who undergo a ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Hundreds of ... behalf of women who were allegedly injured due to ... in New Jersey’s Bergen County Superior Court, Bernstein Liebhard ... on August 15, 2014, the Court has established procedures ... Mirena lawsuits that are part of the proceeding’s initial ...
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... may help older women avoid a condition that causes a ... postmenopausal women had a 10 percent lower risk of developing ... report in the Aug. 20 issue of the Journal ... this protection against the heart rhythm disorder even if they ...
(Date:8/20/2014)... August 20, 2014 Park Cities Pet ... NAPPS Presents 4 Pets supply donation drive that benefits the ... a national campaign that coincides with the Humane Society of ... November 2nd through 8th, 2014. , As part of their ... supply and monetary donations for the Presents 4 Pets drive ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
Breaking Medicine News(10 mins):Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2
... vaccination and a lack of time as main reasons adults avoid ... ... December 10, 2008 -- A new survey of approximately 4,000 American ... against the flu this season. The survey is the first of ...
... Dec. 10 Markel Corporation is,pleased to announce the ... insurance product. DataBreach(SM) helps businesses manage,risk associated with their ... information in their custody or care. , ... to the increase in identity theft,that has been plaguing ...
... might yield new insights into eating disorders, experts say ... verifying what many overeaters have suspected for a long ... sweetener seems to prompt the same chemical changes in ... as cocaine and heroin. , The findings were to ...
... Healthcare Management Systems,Inc.(R) (HMS) hospital customers completed three paintings ... were entered into a drawing,to receive the paintings to ... Recipients of the 4-foot by 6-foot, multiple-canvas paintings were,announced ... HMS, annual,conference. , , ...
... to Attempt to Prevent Complete Vision Loss in Patient ... Dec. 10 NeoVista, Inc., announced today that ... the company,s "compassionate case" waiver to utilize its novel ... with an advanced form of the disease who did ...
... children, new government survey says , , WEDNESDAY, Dec. ... U.S. adults and 12 percent of children use some ... government survey finds. , Complementary and alternative medicine -- ... a collection of wide-ranging medical and health care systems, ...
Cached Medicine News:Health News:Mid-Season Flu Immunization Rates are Too Low 2Health News:Mid-Season Flu Immunization Rates are Too Low 3Health News:Mid-Season Flu Immunization Rates are Too Low 4Health News:Mid-Season Flu Immunization Rates are Too Low 5Health News:Markel Corporation Announces New DataBreach(SM) Privacy Liability Coverage 2Health News:Study Suggests Sugar May Be Addictive 2Health News:Study Suggests Sugar May Be Addictive 3Health News:HMS Donates Hospital Art 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 2Health News:FDA Grants NeoVista's Request to Utilize Novel Wet AMD Treatment in Compassionate Case 3Health News:38% of U.S. Adults Use Alternative Treatments 2Health News:38% of U.S. Adults Use Alternative Treatments 3
Black elastomer. Smooth finish. Non-Sterile....
All oral and nasal airways are manufactured with smooth, rounded edges for increased patient comfort and safety., ,Portex® offers a broad selection of airways for a variety of clinical applicati...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Medicine Products: